Intrathecal dexmedetomidine for cesarean delivery: a scoping review
Authors' conclusion
Dexmedetomidine may be a valuable intrathecal adjuvant for cesarean delivery but the quality of study design and data reporting in the 48 publications was extremely poor.
Study context
- Population
- Patients undergoing cesarean delivery receiving intrathecal dexmedetomidine48 publications
- Participants
- 2,002 patients
- Outcome
- Identification of all publications reporting on ITDex for cesarean delivery
Methodological detailsPRISMA-ScR guidelines, randomized controlled trials (RCTs) and observational trials
- PRISMA-ScR guidelines
- RCTs and observational trials
Main finding
As reported in the abstract
Publications on ITDex for cesarean delivery
- Publications identified (2015–October 2024)
- 48
- RCTs
- 43
- Observational trials
- 3
- Case reports/series
- 2
- Intrathecal dexmedetomidine (ITDex) dose range (μg)
- 1-35
- Primary outcome stated, studies
- 31 (65 %)
- Dose-ranging studies
- 7
- Studies with fentanyl co-administration
- 1
- Studies with morphine co-administration
- 0
- Studies comparing ITDex vs clonidine (clonidine 15-75 μg)
- 3
- Studies reporting shivering
- 35
- Studies reporting block characteristics
- 36
- Studies evaluating postoperative analgesia
- 38
- Studies reporting pain during cesarean delivery
- 9
Observational data: associations, not effects.
Original publication
Intrathecal dexmedetomidine for cesarean delivery: a scoping review. Int J Obstet Anesth. Published 23 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →